News of Note—Bristol-Myers’ cancer vaccine, Bharat Biotech and more

non
In this week's news of note, a Bristol-Myers Squibb's cancer vaccine candidate enters human study. (Pixabay)

Here's some other vaccine news of note for the week.

> A Bristol-Myers Squibb cancer vaccine that has cured 97% of tumors in mouse studies has been approved for human trials at Stanford University. U.S. News & World Report article

> The WHO has recommended the introduction of the world’s first typhoid conjugate vaccine, Typbar-TCV, developed by Bharat Biotech, for infants and children over 6 months of age in typhoid-endemic countries. Release

> Sellas touted phase 2b results that showed its cancer vaccine NeuVax’s ability in prolonging disease-free survival when combined with Herceptin in a group of breast cancer patients. Endpoints News article

> The Global Health Innovative Technology Fund has awarded the University of Florida and partners in the U.S. and Japan $3.2 million to develop a new malaria vaccine. Release

> Through a HK$98.75 ($12.6 million) fund, Hong Kong will provide free HPV vaccination to girls from low-income families. South China Morning Post article

> Archivel Farma has signed a deal with Laboratorios Silanes to develop and commercialize Ruti, a therapeutic vaccine against tuberculosis, in Mexico. Release

Suggested Articles

GSK's Shingrix has generated blockbuster sales early in the launch, but there's a lot of remaining opportunity, an exec said at JPM.

Quickly after Merck's world-first Ebola vaccine approval in Europe, U.S. authorities licensed the shot.

In an effort to stop an Ebola outbreak that has claimed 2,200 lives at the Rwanda border, J&J is shipping 200,000 doses of its vaccine to the country.